Evommune, Inc. (EVMN)

NYSEHealth CareBiotechnologySnapshot 2026-10-23

$5.10-2.11%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Evommune, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	3.33M
EPS	—	-0.911
Annual ending 2026-12-31
Revenue	—	3.13M
EPS	—	-3.45
Annual ending 2027-12-31
Revenue	—	222,222
EPS	—	-3.564

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Advance Atopic Dermatitis Phase 2b data in H2 2026	It is advancing Phase 2b data for atopic dermatitis in H2 2026.	Under Pressure	Phase 2b data not advanced or negative by end of H2 2026	Phase 2b AD trial missed primary endpoint EVO756 Phase 2b AD trial missed primary endpoint in September 2026. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Mitigate impact of recent litigation filed in June 2026	A supporting condition in Evommune, Inc.'s published investment case. The stated target is No material negative impact from litigation by end 2026.	Under Pressure	Litigation causes trial delays or material financial loss	Trial failure confirmed News reports EVO756 trial missed primary endpoint, undermining product advancement and causing significant stock decline. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve at least $13 million revenue in 2026	A primary condition in Evommune, Inc.'s published investment case. The stated target is >=13 million USD.	Broken	revenue falls below $10 million in FY26	Revenue: $0 FY2026-Q2; GAAP. Published target: >=13 million USD. Target period is not explicitly aligned with this observation. Source published Aug 6, 20260 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-3.56

$-3.21 → $-3.56 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-3.21	$1,250,000	7 / 5
2026-07-25	$-3.24	$1,250,000	8 / 8
2026-07-26	$-3.24	$1,250,000	8 / 8
2026-07-27	$-3.24	$1,250,000	8 / 8
2026-07-28	$-3.21	$1,250,000	7 / 5
2026-07-29	$-3.24	$1,250,000	8 / 8
2026-07-30	$-3.24	$1,250,000	8 / 8
2026-07-31	$-3.21	$1,250,000	7 / 5
2026-08-01	$-3.21	$1,250,000	7 / 5
2026-08-02	$-3.24	$1,250,000	8 / 8
2026-08-03	$-3.21	$1,250,000	7 / 5
2026-08-04	$-3.21	$1,250,000	7 / 5
2026-08-05	$-3.21	$1,250,000	7 / 5
2026-08-06	$-3.24	$1,250,000	8 / 8
2026-08-07	$-3.21	$1,250,000	7 / 5
2026-08-08	$-3.27	$1,428,570	8 / 7
2026-08-09	$-3.21	$1,250,000	7 / 5
2026-08-10	$-3.27	$1,428,570	8 / 7
2026-08-11	$-3.21	$1,250,000	7 / 5
2026-08-12	$-3.21	$1,250,000	7 / 5
2026-08-13	$-3.36	$875,000	10 / 8
2026-08-14	$-3.21	$1,250,000	7 / 5
2026-08-15	$-3.21	$1,250,000	7 / 5
2026-08-16	$-3.21	$1,250,000	8 / 5
2026-08-17	$-3.21	$1,250,000	8 / 5
2026-08-18	$-3.21	$1,250,000	8 / 5
2026-08-19	$-3.21	$1,250,000	8 / 5
2026-08-20	$-3.44	$1,250,000	8 / 5
2026-08-21	$-3.44	$1,250,000	8 / 5
2026-08-22	$-3.44	$1,250,000	8 / 5
2026-08-23	$-3.44	$1,250,000	8 / 5
2026-08-24	$-3.44	$1,250,000	8 / 5
2026-08-25	$-3.44	$1,250,000	8 / 5
2026-08-26	$-3.44	$1,250,000	8 / 5
2026-08-27	$-3.44	$1,250,000	8 / 5
2026-08-28	$-3.44	$1,250,000	8 / 5
2026-08-29	$-3.47	$1,250,000	9 / 6
2026-08-30	$-3.47	$1,250,000	9 / 6
2026-08-31	$-3.47	$1,250,000	9 / 6
2026-09-01	$-3.47	$1,250,000	9 / 6
2026-09-02	$-3.47	$1,250,000	9 / 6
2026-09-03	$-3.47	$1,250,000	9 / 6
2026-09-04	$-3.47	$1,250,000	9 / 6
2026-09-05	$-3.47	$1,250,000	9 / 6
2026-09-06	$-3.47	$1,250,000	9 / 6
2026-09-07	$-3.47	$1,250,000	9 / 6
2026-09-08	$-3.47	$1,250,000	9 / 6
2026-09-09	$-3.47	$1,250,000	9 / 6
2026-09-10	$-3.49	$250,000	9 / 6
2026-09-11	$-3.42	$250,000	9 / 6
2026-09-12	$-3.42	$250,000	9 / 6
2026-09-13	$-3.42	$250,000	9 / 6
2026-09-14	$-3.42	$250,000	9 / 6
2026-09-15	$-3.42	$250,000	9 / 6
2026-09-16	$-3.42	$250,000	9 / 6
2026-09-17	$-3.42	$250,000	9 / 6
2026-09-18	$-3.42	$250,000	9 / 6
2026-09-19	$-3.55	$250,000	9 / 6
2026-09-20	$-3.55	$250,000	8 / 6
2026-09-21	$-3.55	$250,000	8 / 6
2026-09-22	$-3.55	$250,000	8 / 6
2026-09-23	$-3.55	$250,000	8 / 6
2026-09-24	$-3.55	$250,000	8 / 6
2026-09-25	$-3.55	$250,000	8 / 6
2026-09-26	$-3.55	$250,000	8 / 6
2026-09-27	$-3.55	$250,000	8 / 6
2026-09-28	$-3.55	$250,000	8 / 6
2026-09-29	$-3.55	$250,000	8 / 6
2026-09-30	$-3.55	$250,000	8 / 6
2026-10-01	$-3.55	$250,000	9 / 6
2026-10-02	$-3.55	$250,000	9 / 6
2026-10-03	$-3.55	$250,000	9 / 6
2026-10-04	$-3.55	$250,000	9 / 6
2026-10-05	$-3.55	$250,000	9 / 6
2026-10-06	$-3.55	$250,000	9 / 6
2026-10-07	$-3.55	$250,000	9 / 5
2026-10-08	$-3.55	$250,000	9 / 5
2026-10-09	$-3.55	$250,000	9 / 5
2026-10-10	$-3.55	$250,000	9 / 5
2026-10-11	$-3.55	$250,000	9 / 5
2026-10-12	$-3.55	$250,000	9 / 5
2026-10-13	$-3.55	$250,000	9 / 5
2026-10-14	$-3.56	$222,222	9 / 5
2026-10-15	$-3.56	$222,222	9 / 5
2026-10-16	$-3.56	$222,222	9 / 5
2026-10-17	$-3.56	$222,222	9 / 5
2026-10-18	$-3.56	$222,222	9 / 5
2026-10-19	$-3.56	$222,222	9 / 5
2026-10-20	$-3.56	$222,222	9 / 5
2026-10-21	$-3.56	$222,222	9 / 5
2026-10-22	$-3.56	$222,222	9 / 5
2026-10-23	$-3.56	$222,222	9 / 5
2026-10-24	$-3.56	$222,222	9 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	10	0
2026-06-01	11	2
2026-07-01	8	2
2026-08-01	9	2
2026-09-01	9	2
2026-10-01	9	3

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 9 Buy / Strong Buy · 3 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

UBSOct 11

$8.00New observation · no comparable prior

$0$4.40$8.80

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Advance Atopic Dermatitis Phase 2b data in H2 2026Published status: Under Pressure
Mitigate impact of recent litigation filed in June 2026Published status: Under Pressure
Achieve at least $13 million revenue in 2026Published status: Broken

Next proof point

Dec 10, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.7%Typical daily move · historical

Downside history

-83.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Evommune, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative, loss-making biotechnology business whose multi-year view depends on clinical progress and its cash runway. The thesis is on watch, with recent financial performance weak and overall risk elevated.

What's priced into Evommune, Inc.

The valuation signal is mixed: EVMN is modeled as cheap versus peers, but the overall priced-in tag is stretched. Model confidence is low, so the evidence does not clearly show how much of the clinical and financial risk the market already reflects.

What the fundamentals likely do

Near term, weak recent performance and an elevated risk of an earnings miss make results and guidance important. Management is maintaining cash, with cash and investments rising to $288.0 million in 2026-Q2, but EVO756 missed its atopic dermatitis primary endpoints and that program was discontinued in the indication. EVO756 continues in migraine, while EVO301 Phase 2b planning remains underway for mid-2027.

What Evommune, Inc. hinges on

The multi-year thesis depends on progress in migraine and EVO301, alongside management maintaining cash to support operations through 2028. Near term, a guidance cut or further weakening in jobs data would add pressure; continued strong results and guidance from healthcare bellwethers could support sector momentum.